Arxx Therapeutics

What Arxx Therapeutics does

Arxx Therapeutics, appearing to operate publicly as Calluna Pharma, is a privately held clinical-stage biotechnology company founded in 2018 and headquartered in Oslo, Norway. The company develops first-in-class monoclonal antibodies with a unique mechanism of action targeting upstream disease amplifiers of inflammation and non-resolving tissue fibrosis, addressing indications of high unmet medical need. Its lead clinical asset, Aurora IPF, is a first-in-class antibody currently in a Phase 2 clinical study for idiopathic pulmonary fibrosis (IPF).

The underlying technology platform centers on antibodies directed at upstream drivers of inflammation and fibrosis, with the stated strategic intent that the same mechanism could be applied across multiple fibrotic and inflammatory conditions. The company describes itself as a 'lean, committed team' of 11–50 employees, co-founded by Rizwan I. Hussain and Jonas Hallén (Chief Medical & Development Officer). Distribution is consistent with a clinical-stage biotech: clinical trial sites and, on approval, traditional pharmaceutical distribution channels targeting enterprise payers and prescribing physicians.

The company is pre-commercial: no product revenue is disclosed, no funding rounds are documented in the source data, and the business model going forward implicitly relies on eventual out-licensing, partnership, or commercialization economics typical of clinical-stage antibody developers. Marketing and corporate communications are limited to a corporate website and a LinkedIn presence.

Name

Arxx Therapeutics

Legal name

Calluna Pharma

Website

https://arxxtx.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Arxx Therapeutics, operating as Calluna Pharma, is a privately held, clinical-stage biotech in Oslo, Norway developing first-in-class monoclonal antibodies that target upstream amplifiers of inflammation and fibrosis, with lead asset Aurora IPF in a Phase 2 study for idiopathic pulmonary fibrosis.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

akta.pro primary industry

Plasma-Derived Protease Inhibitors & Complement Modulators (e.g., C1 Esterase Inhibitor) (HLAIAHAF)

Keywords

• Antibody therapeutics
• Fibrosis treatment
• Monoclonal antibodies
• Inflammation therapeutics
• Biopharmaceutical R&D

Headquarters

HQ city

Oslo

HQ country

Norway

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Distribution channels1 record

Marketing channels3 records

Core offering

Arxx Therapeutics develops a first-in-class monoclonal antibody with a unique mechanism of action targeting non-resolving tissue fibrosis. Its lead clinical-stage product, Aurora IPF, is a Phase 2 antibody therapeutic for idiopathic pulmonary fibrosis that targets upstream disease amplifiers in inflammation and fibrosis, addressing root causes rather than downstream symptoms. The pipeline is positioned for application across multiple medical conditions involving fibrosis and inflammation of high unmet medical need.

Product overview

Calluna Pharma is a biotech company developing first-in-class clinical-stage antibodies for fibrosis and inflammation. Their lead product is Aurora IPF, which is undergoing Phase 2 clinical trials for idiopathic pulmonary fibrosis. The company focuses on targeting upstream disease amplifiers applicable across various medical conditions.

Differentiator

Problem solved

Functional benefit

Products and services

• Aurora IPF First-in-class clinical-stage monoclonal antibody targeting upstream disease amplifiers for idiopathic pulmonary fibrosis (IPF), currently in Phase 2 clinical study. It is intended for patients with progressive fibrotic lung disease where existing therapies are insufficient.

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Recent moves3 records

Expansion highlights3 records

Direct peers

• Pliant Therapeutics: Clinical-stage biotech developing therapeutics for idiopathic pulmonary fibrosis and other fibrotic diseases; closest direct competitor to Calluna on the IPF/antibody-and-fibrosis axis and a benchmark for valuation trajectories at Phase 2.
• Vicore Pharma: Swedish clinical-stage company developing therapeutics for IPF and systemic sclerosis; very comparable Nordic/European fibrosis-focused biotech at similar stage and scale.
• Galapagos NV: European biotech with a fibrosis and inflammation pipeline (including historically an IPF program); comparable European-headquartered, inflammation/fibrosis-focused clinical-stage biotech with similar capital-markets profile.
• FibroGen: Developed pamrevlumab for IPF and other fibrotic indications; one of the better-known mid-cap pure-play IPF/fibrosis biotechs and a direct historical analog for Calluna's Phase 2 anti-fibrotic antibody strategy.

Broad incumbents

• United Therapeutics: Pulmonary-focused biotech with a Tyvaso franchise and ongoing IPF program; comparable mid-cap specialty pulmonary company with relevant fibrosis/ILD development experience.
• Boehringer Ingelheim (OFEV/nintedanib): Maker of OFEV (nintedanib), one of two approved IPF therapies; sets the efficacy/safety benchmark any new IPF asset must clear and is the dominant incumbent Calluna must differentiate against.
• Roche (Esbriet/pirfenidone): Markets Esbriet (pirfenidone), the other standard-of-care IPF therapy; established the regulatory and clinical endpoint framework for IPF approvals that Aurora IPF will be measured against.

Emerging players

• Morphic Holding: Clinical-stage biotech developing oral integrin therapies for fibrosis, including IPF; comparable smaller-cap fibrosis-pure-play with overlapping target patient population and clinical-development pathway.
• Redx Pharma: UK-based clinical-stage biotech with programs targeting fibrosis and inflammation; smaller peer with adjacent anti-fibrotic discovery capabilities and similar development-stage profile.

Others

• AbCellera Biologics: Antibody discovery platform partner for many biotech programs; relevant ecosystem comparator for a monoclonal antibody-focused biotech evaluating discovery partnerships and platform scalability.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/arxx-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arxx Therapeutics